This bill adds a new section (1120A) to title 38 that treats specified diseases as service-connected for members of the Armed Forces who received a COVID‑19 vaccine “under orders” during the window beginning August 24, 2021 and ending January 10, 2023. The presumption applies even where there is no in-service record of the disease and names myocarditis, pericarditis, thrombosis with thrombocytopenia syndrome, and Guillain‑Barré Syndrome as covered conditions, while giving the Secretary authority to add others.
The measure also compels the VA to produce identical, recurring data reports to the Veterans’ Affairs Committees (every 60 days for four years) showing claim volumes and dispositions, and to post those reports publicly. For benefits, adjudication, and budget teams, the bill can both accelerate awards for eligible claimants and create a sustained administrative and fiscal footprint for the Department of Veterans Affairs.
At a Glance
What It Does
Creates a statutory presumption of service-connection under 38 U.S.C. for certain diseases tied to COVID‑19 vaccination for service members who received such vaccines under orders during the statutory date window. It lists four named conditions and lets the VA Secretary add additional diseases after a determination of a "positive association." The bill also requires recurring, disaggregated reporting to Congress and public posting.
Who It Affects
Veterans and former service members who received a COVID‑19 vaccine under DoD orders during Aug 24, 2021–Jan 10, 2023 and later develop the named diseases; VA claims adjudicators and appeals bodies; DoD personnel offices that must supply vaccination records; and federal budget and benefits administrators who manage compensation payouts.
Why It Matters
By statutorily shifting the initial burden of proof for the listed conditions, the bill will likely increase the number of presumptive awards and change how VA adjudicators evaluate causation. The frequent reporting requirement also creates near-real-time transparency intended to track claim trajectories and agency responsiveness.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The heart of the bill is a new 38 U.S.C. section (1120A) that instructs the VA to treat specified diseases as having been incurred or aggravated in service when they occur in a member of the Armed Forces who received a COVID‑19 vaccine “under orders” between August 24, 2021 and January 10, 2023. The statutory text says this should be true “notwithstanding” an absence of in-service medical records evidencing the disease, which moves the practical burden onto the Department to accept service-connection unless it can rebut the presumption under existing law.
The statute names four conditions—myocarditis, pericarditis, thrombosis with thrombocytopenia syndrome (TTS), and Guillain‑Barré Syndrome—and creates a one-way mechanism for expansion: the Secretary may add other diseases if she determines a positive association exists, and must notify the Veterans’ Affairs Committees when she does so. The bill does not define “positive association,” leaving the evidentiary yardstick for additions to agency practice or later rulemaking.To track the effect of the new presumption, the VA must submit a report to the Veterans’ Affairs Committees within 60 days of enactment and then every 60 days for the next four years.
Each report must tally total claims tied to COVID‑19 vaccine–associated diseases and break them down by disposition—approved, denied with no further action, denied with supplemental claim, denied with higher-level review, denied with Board appeal—and list pending claims. The statute also requires the VA to post the reports and any explanatory material publicly on an appropriate Department website.The bill closes with a definitional clause: “COVID‑19 vaccine” means vaccines licensed under PHS Act section 351 or authorized under the FDA emergency use authority.
A clerical amendment inserts the new section into the chapter table of contents. The text does not specify certain operational details—most notably the precise temporal trigger for when a disease is considered to have “become manifest”—so adjudicators and policy teams will need to develop guidance once the statute is operative.
The Five Things You Need to Know
The presumption applies only to service members who received a COVID‑19 vaccine “under orders” between August 24, 2021 and January 10, 2023.
Four conditions are named explicitly: myocarditis, pericarditis, thrombosis with thrombocytopenia syndrome (TTS), and Guillain‑Barré Syndrome; the Secretary may add other diseases after a determination of a “positive association.”, When the Secretary adds a disease under that authority, she must notify the Senate and House Veterans’ Affairs Committees of the determination.
The VA must deliver a report to the Veterans’ Affairs Committees within 60 days of enactment and every 60 days for four years, with disaggregated claim counts (approved; denied/no further action; denied + supplemental claim; denied + higher-level review; denied + Board appeal) and a count of pending claims, and must publish the reports online.
The statute defines “COVID‑19 vaccine” to include products licensed under 42 U.S.C. § 262 (PHS Act §351) or authorized under FDA emergency use authority (21 U.S.C. § 360bbb‑3).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the "Justice for Vaccine Injured Veterans Act of 2025." This is a purely titular provision but signals the bill’s intent and scope for lawmakers and stakeholders.
Findings and sense of Congress
Summarizes the Department of Defense vaccination memorandum (Aug 24, 2021), vaccination rates, separations for refusal, and the rescission of the mandate in Jan 2023; and states the Sense of Congress that the actions caused "irreparable harm" to force health and readiness. These findings do not create legal entitlements but frame legislative intent and may be cited in implementation or litigation to clarify congressional purpose.
Statutory presumption for specified vaccine-associated diseases
Adds a presumption of service connection for diseases that “become manifest” in a member who received a COVID‑19 vaccine under orders during the listed date window. Practically, adjudicators must treat a covered disease as incurred in or aggravated by service even when no in-service medical evidence exists, subject to the constraints of related provisions of title 38. That change alters claim evaluation by shifting the initial evidentiary posture away from the claimant for the enumerated cohort.
Named conditions and Secretary's addition authority
Lists myocarditis, pericarditis, TTS, and Guillain‑Barré Syndrome as covered conditions. Subsection (b)(4) lets the Secretary add diseases based on a determination of a "positive association" with the COVID‑19 vaccine; subsection (c) requires the Secretary to notify the Veterans’ Affairs Committees when she makes such an addition. The statutory standard for adding diseases is not defined, leaving scientific and procedural criteria to agency implementation.
Reporting, public posting, definition of vaccine, and table update
Imposes a reporting cadence—first report within 60 days of enactment, then every 60 days for four years—with specified disaggregated claim categories and pending counts, and requires the VA to post the reports and any contextual material online. Defines COVID‑19 vaccine to include both licensed and EUA products, which matters for eligibility. Finally, the bill inserts the new section into the chapter table of sections to make it part of the existing statutory structure.
This bill is one of many.
Codify tracks hundreds of bills on Veterans across all five countries.
Explore Veterans in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Service members and veterans who received a COVID‑19 vaccine under DoD orders during Aug 24, 2021–Jan 10, 2023 and later develop one of the named conditions — the presumption eases the path to VA compensation by reducing proof requirements.
- Surviving spouses and dependents of affected veterans in cases where a covered disease contributes to death — the presumption can establish service-connection more readily for dependency and indemnity claims.
- Veterans Service Organizations and accredited claims representatives — simpler presumptive standards and transparent reporting can streamline representation and case tracking.
- Veterans who value transparency — the 60‑day public reporting requirement gives advocates, researchers, and the public recurring access to claim metrics that are otherwise sporadic or aggregated.
Who Bears the Cost
- Department of Veterans Affairs (VBA and VHA) — increased claims adjudication workload, expanded benefit outlays for presumptive awards, and the operational cost of producing frequent, disaggregated reports and maintaining public portals.
- Federal budget/taxpayers — broader presumptions generally increase long‑term compensation and potential health care obligations payable from federal funds.
- Department of Defense — operational and personnel offices may face additional record‑production requests to verify that claimants received vaccines "under orders," and may be a source of documentary disputes.
- Appeals and oversight bodies — if the VA denies cases or contests causation beyond the statutory presumption, the Board of Veterans' Appeals and courts may see higher litigation volume, imposing indirect staffing and processing costs.
Key Issues
The Core Tension
The bill forces a trade-off between rapidly expanding access to benefits for veterans who link serious post‑vaccine conditions to service and preserving a rigorous, evidence‑based adjudication standard that guards against speculative causation and unchecked fiscal exposure; implementation will hinge on how the VA defines the temporal scope of qualification and the evidentiary threshold for adding new diseases.
The statute contains structural ambiguities that matter for implementation. The bill’s short title and introductory text reference diseases that "become manifest during the one-year period following the receipt of the vaccine," but the operative statutory language added at 38 U.S.C. 1120A ties coverage to members who "received a COVID‑19 vaccine under orders" in the Aug 24, 2021–Jan 10, 2023 window and treats a disease becoming manifest in those members as service-connected.
The absence of an explicit one‑year manifestation window in the operative text creates uncertainty about how long after vaccination a condition qualifies for the presumption and invites varying interpretations by adjudicators and litigants.
Another key implementation question is the evidentiary standard for adding diseases: the Secretary may authorize additional conditions based on a "positive association," a phrase the bill does not define or qualify (e.g., strength of evidence, required peer-reviewed studies, or advisory committee review). That discretion enables responsive policy but risks inconsistent additions or politicized decision‑making.
The 60‑day reporting cadence improves transparency but imposes recurring administrative costs and may incentivize production of high‑level numbers without sufficient clinical context. Finally, treating absence of in‑service records as irrelevant for presumption purposes shifts the burden to the Department to rebut service-connection, which aligns with a claimant‑favorable posture but increases fiscal and evidentiary pressures on the VA.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.